Share
𝕏 Facebook LinkedIn

Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line.

AI: Melanie Research RF Safe Research Library Jan 1, 2023 NEUTRAL MEDIUM

This in vitro study tested whether a 50 Hz, 20 mT extremely low-frequency electromagnetic field (ELF-EMF) enhances the cytotoxic effects of doxorubicin (DOX) in the MCF-7 breast cancer cell line. The authors report that combining ELF-EMF with low-dose DOX reduced cell viability at lower DOX concentrations than DOX alone and was associated with increased ROS, G0-G1 cell-cycle arrest, and apoptosis. The work suggests a potential synergistic anti-tumor effect under the studied laboratory conditions, but it does not address human exposure or clinical efficacy.

Key points

  • The study is an in vitro experiment in the MCF-7 breast cancer cell line.
  • Exposure was ELF-EMF at 50 Hz and 20 mT, assessed alongside doxorubicin treatment.
  • Cell viability was measured by MTT at 12, 24, and 48 hours.
  • DOX alone showed concentration- and time-dependent cytotoxicity within 24 hours.
  • The combination reportedly reduced viability to 50% at >0.25 μM DOX (24 h), versus 2 μM DOX alone for a similar reduction.
  • At 0.25 μM DOX, adding ELF-EMF was reported to increase ROS and DOX-induced apoptosis.
  • Flow cytometry findings were described as enhanced G0-G1 arrest and apoptotic cell death with the combined treatment.

Referenced studies & papers

Source: Open original

AI-generated summaries may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.